-
61.发明授权
公开(公告)号：US4087384A
公开(公告)日：1978-05-02
申请号：US752319
申请日：1976-12-20
申请人： Robert E. Davis
发明人： Robert E. Davis
CPC分类号： B01D53/944 , B01J23/44
摘要： A method of lowering undesirable vehicle exhaust emissions includes preparing a catalyst for use in the exhaust stream of the vehicle. The method includes impregnating one group of alumina substrates with platinum, impregnating another group of alumina substrates with palladium, and the mixing the first and second groups of impregnated substrates.
摘要翻译： 减少不期望的车辆废气排放的方法包括制备用于车辆排气流中的催化剂。 该方法包括用铂浸渍一组氧化铝衬底，用钯浸渍另一组氧化铝衬底，并混合第一组和第二组浸渍衬底。
-
62.发明申请SELECTIVE SEROTONIN 2A/2C RECEPTOR INVERSE AGONISTS AS THERAPEUTICS FOR NEURODEGENERATIVE DISEASES 有权选择性丝氨酸蛋白酶2A / 2C受体反转激动剂作为神经病变性疾病的治疗剂公开(公告)号：US20120277221A1
公开(公告)日：2012-11-01
申请号：US13539011
申请日：2012-06-29
IPC分类号： A61K31/445 , A61K31/519 , A61P25/00 , A61K31/551
CPC分类号： A61K31/4468 , A61K9/20 , A61K31/194 , A61K45/06 , C07C59/255 , C07D211/58 , A61K2300/00
摘要： Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
摘要翻译： 与式（I）化合物（一种新型和选择性的5HT2A / 2C受体反向激动剂）的行为药理学数据证明了在精神病和运动障碍模型中的体内功效。 这包括逆转MK-801诱导的运动行为的活动，表明该化合物可能是MPTP灵长类运动障碍模型中有效的抗精神病药和活性，表明作为抗运动障碍剂的功效。 这些数据支持5HT2A / 2C受体反向激动作用可能赋予人类抗精神病和抗运动障碍功效的假说，并表明使用式（I）化合物和相关药物作为帕金森病，相关人类神经变性疾病的新疗法， 和精神病。
-
63.发明申请公开(公告)号：US20100227886A1
公开(公告)日：2010-09-09
申请号：US12759664
申请日：2010-04-13
IPC分类号： A61K31/4468 , A61P25/18
CPC分类号： A61K31/4468 , A61K9/20 , A61K31/194 , A61K45/06 , C07C59/255 , C07D211/58 , A61K2300/00
摘要： Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
-
64.发明申请Selective Serotonin 2A/2C Receptor Inverse Agonists as Therapeutics for Neurodegenerative Diseases 有权选择性5-羟色胺2A / 2C受体反向激动剂作为治疗神经退行性疾病公开(公告)号：US20100227885A1
公开(公告)日：2010-09-09
申请号：US12759662
申请日：2010-04-13
IPC分类号： A61K31/4468 , A61P25/28
CPC分类号： A61K31/4468 , A61K9/20 , A61K31/194 , A61K45/06 , C07C59/255 , C07D211/58 , A61K2300/00
摘要： Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.
摘要翻译： 与式（I）化合物（一种新型和选择性的5HT2A / 2C受体反向激动剂）的行为药理学数据证明了在精神病和运动障碍模型中的体内功效。 这包括逆转MK-801诱导的运动行为的活动，表明该化合物可能是MPTP灵长类运动障碍模型中有效的抗精神病药和活性，表明作为抗运动障碍剂的功效。 这些数据支持5HT2A / 2C受体反向激动作用可能赋予人类抗精神病和抗运动障碍功效的假说，并表明使用式（I）化合物和相关药物作为帕金森病，相关人类神经变性疾病的新疗法， 和精神病。
-
65.发明授权Apparatus and method to transfer data from a tire pressure monitor tool to a remote output device such as a printer 有权将数据从轮胎压力监测工具传送到诸如打印机的远程输出装置的装置和方法公开(公告)号：US07589619B2
公开(公告)日：2009-09-15
申请号：US11650513
申请日：2007-01-08
IPC分类号： B60C23/00
CPC分类号： B60C23/0408 , B60C23/0479
摘要： A tire pressure monitoring tool transmits a triggering signal to a tire sensor; receives a reporting signal from the tire sensor; extracts data from the reporting signal; stores the extracted data; and transmits the stored data to an external device. The transmitted stored data is in a predetermined order, and in a text format.
摘要翻译： 轮胎压力监测工具将触发信号传送到轮胎传感器; 从轮胎传感器接收报告信号; 从报告信号中提取数据; 存储提取的数据; 并将存储的数据发送到外部设备。 所发送的存储数据是以预定的顺序和文本格式。
-
66.发明申请公开(公告)号：US20090209525A1
公开(公告)日：2009-08-20
申请号：US12340393
申请日：2008-12-19
IPC分类号： A61K31/551 , C12Q1/68 , G01N33/53 , A61K31/538 , A61K31/445 , A61K31/195 , A61K31/46 , A61K31/4439 , A61K31/4025
CPC分类号： G01N33/9406 , G01N2500/04
摘要： A method developed to identify receptor modulators, involving providing a mutant receptor, wherein said mutant receptor has a mutation that alters the activity of said mutant receptor compared to a wild type receptor; contacting said mutant receptor with a candidate compound; and determining whether said candidate compound modulates the activity of said mutant receptor.
摘要翻译： 一种开发用于鉴定受体调节剂的方法，涉及提供突变体受体，其中所述突变体受体具有与野生型受体相比改变所述突变受体活性的突变; 使所述突变体受体与候选化合物接触; 以及确定所述候选化合物是否调节所述突变受体的活性。
-
67.发明申请METHOD AND STRUCTURE FOR SEMICONDUCTOR DEVICES WITH SILICON-GERMANIUM DEPOSITS 审中-公开具有硅锗沉积物的半导体器件的方法和结构公开(公告)号：US20090152590A1
公开(公告)日：2009-06-18
申请号：US11955488
申请日：2007-12-13
申请人： Thomas N. Adam , Linda Black , Huajie Chen , Dureseti Chidambarrao , Robert E. Davis , Judson R. Holt , Randolph F. Knarr , Christian Lavoie , Robert J. Purtell , Dominic J. Schepis
发明人： Thomas N. Adam , Linda Black , Huajie Chen , Dureseti Chidambarrao , Robert E. Davis , Judson R. Holt , Randolph F. Knarr , Christian Lavoie , Robert J. Purtell , Dominic J. Schepis
IPC分类号： H01L29/78 , H01L21/336
CPC分类号： H01L29/7848 , H01L29/165 , H01L29/665 , H01L29/6656 , H01L29/66636
摘要： A method of forming a semiconductor device including forming a second deposit of silicon-germanium on a first deposit of silicon-germanium, the first deposit formed in a conduction terminal region of a substrate of the semiconductor device and having a first percentage of germanium, and the second deposit having a second percentage of germanium that is less than the first percentage and supports forming a silicide deposit on the second deposit. A structure is also provided.
摘要翻译： 一种形成半导体器件的方法，包括在硅 - 锗的第一沉积物上形成硅 - 锗的第二沉积物，所述第一沉积物形成在所述半导体器件的衬底的导电末端区域中并且具有第一百分比的锗，以及 所述第二沉积物具有小于所述第一百分比的第二百分比的锗，并且在所述第二沉积物上支持形成硅化物沉积物。 还提供了一种结构。
-
68.发明授权公开(公告)号：US06906174B2
公开(公告)日：2005-06-14
申请号：US09809827
申请日：2001-03-16
IPC分类号： G01N33/50 , A61K31/704 , A61K31/7048 , A61K31/7056 , A61K31/7064 , A61K45/00 , A61P3/00 , A61P3/10 , A61P17/06 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/28 , A61P27/16 , A61P35/00 , A61P43/00 , C07H15/256 , C07H15/26 , C07K1/22 , C07K14/47 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12N15/12 , C12N15/62 , C12P21/02 , C12Q1/02 , C12Q1/68 , G01N33/15 , G01N33/53 , G01N33/566 , C07K1/00 , C07K14/00
CPC分类号： C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N15/62 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
-
69.发明授权公开(公告)号：US06906173B2
公开(公告)日：2005-06-14
申请号：US09185904
申请日：1998-11-03
CPC分类号： C12N15/62 , C07K14/47 , C07K2319/00 , C07K2319/07 , C07K2319/21 , C07K2319/23 , C12N2799/021
摘要： Compositions and methods are provided for producing adenine nucleotide translocator (ANT) polypeptides and fusion proteins, including the production and use of recombinant expression constructs having a regulated promoter. ANT ligands and compositions and methods for identifying ANT ligands, agents that bind ANT and agents that interact with ANT are also disclosed.
-
公开(公告)号：US06653094B2
公开(公告)日：2003-11-25
申请号：US09924313
申请日：2001-08-07
IPC分类号： C12Q132
CPC分类号： C12Q1/6883 , G01N33/6893 , G01N2800/042
摘要： The present invention relates to improved diagnostic methods for early detection of a risk for developing type 2 diabetes mellitus in humans, and screening assays for therapeutic agents useful in the treatment of type 2 diabetes mellitus, by comparing the levels of one or more indicators of altered mitochondrial function. Indicators of altered mitochondrial function include enzymes such as mitochondrial enzymes and ATP biosynthesis factors. Other indicators of altered mitochondrial function include mitochondrial mass, mitochondrial number and mitochondrial DNA content, cellular responses to elevated intracellular calcium and to apoptogens, and free radical production. Methods of treating, and of stratifying, human patients as such methods relate to disclosed indicators of altered mitchondrial function are also provided.
-
-
-
-
-
-
-
-
-
搜索结果
105 条记录 (耗时 0.055 秒)
